倫理・公共政策センター

In 2025, legislation based on proposals from the Ethics and Public Policy Center (EPPC) was enacted in Arkansas and Utah. In Arkansas, Governor Sarah Huckabee Sanders signed a law on April 22 addressing infertility through alternatives to in vitro fertilization (IVF), reflecting a model developed by EPPC policy analyst Natalie Dodson.^[17] The law followed the publication of an EPPC report outlining ethical treatments for infertility.

In Utah, Governor Spencer Cox signed SB 334 into law on March 24. The law, based on model legislation by EPPC senior fellow Stanley Kurtz, requires students at Utah State University to complete a year-and-a-half course in Western civilization and a one-semester course in American civics.^[18]

In April 2025, researchers Jamie Bryan Hall and Ryan T. Anderson published a large-scale observational study analyzing the safety of mifepristone, one of two drugs commonly used for medication abortion approved by the FDA in 2000.^[19] Using data from a comprehensive all-payer insurance claims database, the study examined 865,727 mifepristone abortions performed in the United States between 2017 and 2023. The study reported that 10.93 percent of women experienced serious adverse events within 45 days of taking mifepristone. These events included sepsis, infection, hemorrhage, surgery, and hospitalization. The reported complication rate was significantly higher than the less than 0.5 percent rate found in earlier clinical trials referenced by the U.S. Food and Drug Administration (FDA). The authors attributed the discrepancy to differences between clinical trial conditions and real-world medical practice. They argued that current FDA safety protocols are insufficient and recommended reinstating earlier safeguards. These included physician-only prescribing, in-person medical supervision, and mandatory reporting of adverse events. The study concluded that the FDA should reassess the approval and regulation of mifepristone based on updated safety data.^[20]

The methodology for the study has been called into question.^[21] One of the adverse events it relies upon is ectopic pregnancy, which is not caused by nor exacerbated by mifepristone.^[22] Additionally the abortion medication regimen includes misoprostol yet this study includes cases which only mifepristone was taken for reasons possibly unrelated to pregnancy. The analysis is not peer-reviewed nor is it published in a medical journal.

この研究結果は、2025年5月14日の米国上院公聴会で、ジョシュ・ホーリー上院議員がロバート・ケネディ・ジュニア保健福祉長官 との議論の中でこのデータを引用した際に言及された^{。[ 23 ]}これに対し、ケネディ長官は、食品医薬品局長官マーティン・マカリにミフェプリストンの安全性プロファイルの全面的な見直しを行うよう要請したと述べた。2025年6月2日、マカリ長官はホーリー上院議員への書簡で、そのような見直しが行われることを確認した。^{[ 24 ]}